Enhancing HGF and Crossing the Blood-Brain Barrier to Effectively Slow Progression of Neurodegenerative Diseases with Mark Litton Athira Pharma TRANSCRIPT
Download PDFNov 6, 2023
Mark Litton, President and CEO of Athira Pharma, discusses advancements in treating neurodegenerative diseases, highlighting the challenges in treating these diseases. Athira's approach uses the body's natural repair mechanism to enhance the repair and protection of nerve cells. Their lead molecule,...
Nov 6, 2023
Mark Litton, President and CEO of Athira Pharma, discusses advancements in treating neurodegenerative diseases, highlighting the challenges in treating these diseases. Athira's approach uses the body's natural repair mechanism to enhance the repair and protection of nerve cells. Their lead molecule,...
Jul 5, 2023
Chris Hoyt, CEO of KeifeRx, talks about the oral medication being developed that uses tyrosine kinase inhibitors (TKIs) and autophagy to remove unwanted proteins. Research done by Georgetown University on leukemia, led by Dr. Charbel Moussa, found that lower doses of drugs like nilotinib and bosutinib could cross the...
Jul 5, 2023
Chris Hoyt, CEO of KeifeRx, talks about the oral medication being developed that uses tyrosine kinase inhibitors (TKIs) and autophagy to remove unwanted proteins. Research done by Georgetown University on leukemia, led by Dr. Charbel Moussa, found that lower doses of drugs like nilotinib and bosutinib could cross the...
Developing Naturally Derived Psychedelic Medicines with Benjamin Lightburn Filament Health TRANSCRIPT
Download PDFMar 28, 2023
Benjamin Lightburn, Co-Founder and CEO of Filament Health points out that up until now, research with psychedelics has been done with synthetically prepared psychedelic substances. Filament is making a product through natural extraction that results in a medicine containing psilocybin plus over a dozen other active...